Nasdaq-traded Chinese herb company hits near $30 billion market value after speculative surge
Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience company with no revenue, is the latest speculative overseas stock to attract an unusual surge in trading demand.
Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivity disorder and autism, more than tripled on Monday — soaring more than 280% by the close. A 38-for-1 split declared on June 2 took effect on Monday.
The company's year to date performance is off the charts too, having risen 46,000% in 2025. By Monday's close, Regencell, founded in 2014 and traded on Nasdaq under the ticker 'RGC' since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ.
Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data.
Regencell is the latest example of a speculative international stock attracting attention during summer trading. In August, 2022, for example, AMTD Digital, a Hong Kong-based fintech company, climbed 126%, briefly giving it a market value greater than Coca-Cola and Bank of America.
Regencell's market value is now about equal with Nasdaq-traded Lululemon and tops Super Micro Computer and Fifth Third Bancorp.
Earlier this month, Regencell explained the stock split as designed solely "to enhance liquidity in the market for the company's ordinary shares and make the shares more accessible to investors." Stock splits do not change anything fundamentally about a company.
Regencell's surge also came amid an increased focus on alternative medicines after Robert F. Kennedy Jr. was sworn in as Secretary of the U.S. Department of Health and Human Services in February. Kennedy, a vaccine skeptic, has taken steps to discourage routine immunizations in the U.S., last week removing all of the members of a panel that advises the Centers for Disease Control and Prevention on vaccines.
Regencell's stock often makes huge one-day swings. For example, shares jumped roughly 30% on March 21, before dropping 30% the following trading day.
In spite of the wild spike in the stock, little is known about the efficacy and commercialization of the Regencell's treatments for ADHD and Autistic Spectrum Disorders.
Regencell's business centers on a proprietary Traditional Chinese Medicine formula (TCM) developed in a partnership with TCM practitioner Sik-Kee Au using his "Sik-Kee Au TCM Brain Theory." Sik-Kee Au is the father of the Regencell chief executive officer Yat-Gai Au, the company said in a 2022 statement.
Three liquid-based, orally TCM formulae candidates claim to address mild, moderate and severe conditions and only contain natural ingredients such as so-called "detoxication herbs," blood circulation herbs and digestion herbs.
"These TCM formulae form the basis of our TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD," Regencell's website reads.
In its latest annual report filed last October, Regencell said that it had not generated any revenue, nor filed for any regulatory approvals of its TCM formulas. For the fiscal years ended June 2024 and 2023, Regencell incurred total net losses of $4.36 million and $6.06 million, respectively, according to a 20F filing to the SEC.
"We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," read the filing.
Regencell has not responded to a CNBC request for comment.
Regencell's latest patient case study, dated Nov. 15, 2023, said 28 patients were given the treatment over a period of three months in a second efficacy trial and showed an improvement in symptoms of ADHD and ASD, according to the company's webpage.
In an earlier case, Regencell said in a 2021 news release that it treated a dozen patients with suspected or confirmed Covid-19 cases, using a modified version of Au's modified proprietary cold and flu TCM formula. What was described as an improvement of Covid conditions led Regencell to form a joint venture with Honor Epic Enterprises Limited in Sept. 2021 to conduct further tests and commercialize the company's Covid treatment in ASEAN countries, according to the statement.
The stock has attracted little chatter on social media over the past few years. Those comments that have been made suggest both retail trader enthusiasm — and skepticism.
One user on the Reddit page "r/Shortsqueeze" wrote on Monday that Regencell is "trading like a meme coin. Bought a little to see what happens and it dropped 50% right after lol." Another user said in a post made three months ago, "I scalp RGC everyday for a bit of profit." The stock jumped 1,360% in May alone.
On LinkedIn in May, one investor said he "can't stop laughing," after reading the company description. Another post from a user in the pharmaceutical industry, according to his profile, last week said Regencell has become the "stock to watch" after its spike in May on "no official news or catalysts." Another LinkedIn user last month commented on Regencell, saying, "China based, low volume and no official news, bizarro."
On X, one user wrote in a Monday post said, "for #CompleteBullsh__CompanyOfTheYear I nominate regencell."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Liberty Broadband Corporation Announces Record Date and Distribution Date for Spin-Off of GCI Liberty, Inc.
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Liberty Broadband Corporation ('Liberty Broadband') (Nasdaq: LBRDA, LBRDK, LBRDP) announced today that, in connection with the upcoming spin-off (the 'Spin-Off') of its wholly owned subsidiary, GCI Liberty, Inc. ('GCI Liberty'), its Board of Directors has declared a record date of 5:00 p.m., New York City time, on June 30, 2025 (such date and time, the 'Record Date') for the distribution (the 'Distribution') of the GCI Group common stock (as defined below) and set a distribution date of 4:30 p.m., New York City time, on July 14, 2025 for the completion of the Spin-Off (such date and time, as amended, the 'Distribution Date'). In the Spin-Off, if all conditions to the Distribution are satisfied or, if permitted, waived as of the Distribution Date, Liberty Broadband will distribute 0.20 of a share of GCI Liberty's Series A GCI Group common stock, Series B GCI Group common stock and Series C GCI Group common stock (collectively, the 'GCI Group common stock') for each whole share of the corresponding series of Liberty Broadband common stock held as of the Record Date by the holder thereof. Cash (with no interest) will be paid in lieu of fractional shares of GCI Group common stock. Immediately following the Spin-Off, GCI Liberty will be an independent publicly traded company and its businesses, assets and liabilities will initially consist of 100% of the outstanding equity interests in GCI, LLC ('GCI') and its subsidiaries. The completion of the Spin-Off remains subject to satisfaction or, if permitted, waiver of certain conditions, including the receipt of the Regulatory Commission of Alaska's final order approving the transfer of an indirect controlling interest in the GCI Liberty licensee subsidiaries, which Liberty Broadband expects to receive by June 27, 2025. If the conditions to the Distribution are not satisfied or, if permitted, waived by the expected Distribution Date, then Liberty Broadband may defer the Distribution Date. If the Distribution Date is deferred, Liberty Broadband intends to promptly issue a press release and file a Current Report on Form 8-K to report such event. Trading Information Liberty Broadband expects that the shares of Series A GCI Group common stock and Series C GCI Group common stock will be listed on the Nasdaq Global Select Market under the ticker symbols 'GLIBA' and 'GLIBK,' respectively, and that the shares of Series B GCI Group common stock will be quoted on the OTC Markets under the symbol 'GLIBB,' in each case, beginning on July 15, 2025. There is no current trading market for GCI Group common stock, although Liberty Broadband expects that a limited market, commonly known as a 'when-issued' trading market, will develop on or shortly before the Record Date, and that 'regular-way' trading of GCI Group common stock will begin on the first trading day after the Distribution is completed. Following the Distribution, the number and series of shares of Liberty Broadband common stock owned by holders thereof will not change as a result of the Distribution, and Liberty Broadband Series A common stock and Liberty Broadband Series C common stock will continue to trade on the Nasdaq Global Select Market under the symbols 'LBRDA' and 'LBRDK,' respectively, and Liberty Broadband Series B common stock will continue to be quoted on the OTC Markets under the symbol 'LBRDB,' in each case, unless and until the acquisition of Liberty Broadband by Charter Communications, Inc. ('Charter') is consummated. Additional information regarding the Spin-Off is available on Liberty Broadband's Investor Relations site, specifically the presentation entitled '2025 GCI Liberty Investor Conference Call Addendum,' which can be accessed at the following URL: Forward-Looking Statements This communication includes certain forward-looking statements within the meaning the Private Securities Litigation Reform Act of 1995, including certain statements relating to the proposed timing of the Spin-Off of GCI Liberty, the listing of the GCI Group common stock and other matters that are not historical facts. All statements other than statements of historical fact are 'forward looking statements' for purposes of federal and state securities laws. These forward-looking statements generally can be identified by phrases such as 'possible,' 'potential,' 'intends' or 'expects' or other words or phrases of similar import or future or conditional verbs such as 'will,' 'may,' 'might,' 'should,' 'would' or 'could,' or similar variations. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including, without limitation, Liberty Broadband's ability to satisfy the conditions to the Spin-Off and the development of a trading market for the GCI Group common stock. These forward-looking statements speak only as of the date of this communication, and Liberty Broadband and GCI Liberty expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in Liberty Broadband's or GCI Liberty's expectations with regard thereto or any change of events, conditions or circumstances on which any such statement is based. Please refer to the publicly filed documents of Liberty Broadband and GCI Liberty, including the registration statement relating to the Spin-Off of GCI Liberty, and Liberty Broadband's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as such risk factors may be amended, supplemented or superseded from time to time by other reports Liberty Broadband or GCI Liberty subsequently files with the SEC, for additional information about Liberty Broadband, GCI Liberty and the risks and uncertainties related to Liberty Broadband's and GCI Liberty's businesses which may affect the statements made in this communication. About Liberty Broadband Corporation Liberty Broadband Corporation (Nasdaq: LBRDA, LBRDK, LBRDP) operates and owns interests in a broad range of communications businesses. Liberty Broadband's principal assets consist of its interest in Charter and its subsidiary GCI. GCI provides data, mobile, video, voice and managed services to consumer, business, government and carrier customers throughout Alaska, serving more than 200 communities. The company has invested $4.7 billion in its Alaska network and facilities over the past 45 years. Through a combination of ambitious network initiatives, GCI continues to expand and strengthen its statewide network infrastructure to deliver the best possible connectivity to its customers and close the digital divide in Alaska.
CNBC
26 minutes ago
- CNBC
Darden Restaurants beats earnings estimates, as Olive Garden parent predicts growth in 2026
Darden Restaurants on Friday beat Wall Street's earnings and revenue estimates, while the Olive Garden parent predicted solid growth for fiscal year 2026. Shares of Darden rose more than 2% in premarket trading Friday. Here's what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Darden reported fiscal fourth-quarter net income of $303.8 million, or $2.58 per share, compared with $308.1 million, or $2.58 per share, a year earlier. Excluding costs related to its Chuy's Tex Mex acquisition, Darden earned $2.98 per share for the fiscal fourth-quarter ended May 25. Net sales rose 10.6% to $3.3 billion, fueled in part by acquiring 103 Chuy's restaurants and 25 net new restaurants. The Orlando, Florida-based company's same-store sales rose 4.6%, beating StreetAccount estimates of 3.5%. For the full fiscal year 2026, Darden gave a forecast for revenue growth of 7% to 8%, including approximately 2% growth related to having an extra week in the year. It expects adjusted earnings to be in a range of $10.50 to $10.70 per share, including 20 cents related to the additional week. Despite signs of consumers pulling back on spending, Darden Restaurants CEO Rick Cardenas said in March during the company's third-quarter earnings call that dining out has remained a category where consumers continue to treat themselves and splurge. "Our strategy remains the right one for the company, and we will continue to execute it to drive growth and long-term shareholder value," he said in a release Friday. Darden's two standout brands, Olive Garden and LongHorn Steakhouse, reported same-store sales growth that beat expectations. Olive Garden, which accounts for roughly 40% of Dardan's quarterly revenue, saw same-store sales rise 6.9%, beating analysts' expectations of 4.6%. LongHorn's same-store sales increased 6.7%, while analysts were anticipating growth of 5.3%. Darden's fine dining segment, which includes Ruth's Chris Steak House and The Capital Grille, reported a same-store sales decline of 3.3%, compared with the 0.2% decline expected. The company's remaining segment, which includes Cheddar's Scratch Kitchen and Yard House, saw same-store sales growth of 1.2%, compared to estimates of 1.1%. In March, Cheddar's Scratch Kitchen became the next Darden brand, after Olive Garden, to pilot on-demand delivery through a partnership with Uber Direct. At that time, Darden said Cheddar's was conducting the pilot in 10 of its restaurants. The company also announced that on Wednesday, its board of directors authorized a $1 billion share repurchase program, which does not have an expiration date and replaces the previously existing share repurchase authorization. Darden Restaurants stock is up about 19% year-to-date.
Yahoo
32 minutes ago
- Yahoo
With 59% institutional ownership, eHealth, Inc. (NASDAQ:EHTH) is a favorite amongst the big guns
Institutions' substantial holdings in eHealth implies that they have significant influence over the company's share price The top 17 shareholders own 51% of the company Insiders have been buying lately AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Every investor in eHealth, Inc. (NASDAQ:EHTH) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 59% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. In the chart below, we zoom in on the different ownership groups of eHealth. Check out our latest analysis for eHealth Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that eHealth does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of eHealth, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 14% of eHealth shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that 8 Knots Management, LLC is the largest shareholder with 8.1% of shares outstanding. For context, the second largest shareholder holds about 5.6% of the shares outstanding, followed by an ownership of 4.4% by the third-largest shareholder. In addition, we found that Francis Soistman, the CEO has 2.3% of the shares allocated to their name. After doing some more digging, we found that the top 17 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. We can report that insiders do own shares in eHealth, Inc.. As individuals, the insiders collectively own US$7.4m worth of the US$123m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying. With a 21% ownership, the general public, mostly comprising of individual investors, have some degree of sway over eHealth. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. It's always worth thinking about the different groups who own shares in a company. But to understand eHealth better, we need to consider many other factors. Take risks for example - eHealth has 2 warning signs we think you should be aware of. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
